Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Nov 14, 2022 12:27pm
86 Views
Post# 35096924

RE:RE:RE:RE:RE:RE:Buy Replicel Shares

RE:RE:RE:RE:RE:RE:Buy Replicel Shares
Genie29j wrote:

If the Shiseido deal comes to fruition - this stock is going sky high. Easily $10, possibly $20. 


hair loss is a multi billion dollar business. If Replicel truly found a way to solve this, it will be massive. 



At this point it is up to Shiseido to prove RCH-01 is an affective remedy for hair loss.  That is why this Arbitration is so important to the future of Replicel.  Obviously Shiseido sees big value in RCH-01 otherwise they would abandon this Arbitration.  It is a very costly process.  My reason for thinking there will be a settlement before a judgement is rendered is I think the Shiseido lawyers have now seen Replicel's argument and are most likely encouraging them to settle with Replicel rather than wait for a judgement that they will most likley loose.  
What would this settlement entail ?  I suspect it would be a increased monetary injection from Shiseido to Replicel in exchange for a co-development contract allowing them to use the Dermal injector.  If this is the case the future looks rosy for Replicel.
JC I always encourage shareholders to not dream of $10.00 - $20.00 share prices as at this point they only fantasy and not reality.  Let's get to the $1.00 - $2.00 range which would be massive for most of us.  Once there we can start to dream of higher share prices. 

<< Previous
Bullboard Posts
Next >>